Cortexyme (CRTX) 643-participant study in mild to moderate patients with Alzheimer’s disease did not meet statistical significance in its co-primary cognitive and functional endpoints
Go back to Cortexyme (CRTX) 643-participant study in mild to moderate patients with Alzheimer’s disease did not meet statistical significance in its co-primary cognitive and functional endpoints| Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) | Delayed: 1.95 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.95 | 52 Week High | $10.37 | |||
| Open | $1.95 | 52 Week Low | $5.32 | |||
| Day High | $1.95 | P/E | 6.50 | |||
| Day Low | $1.95 | EPS | $0.30 | |||
| Volume | 61,697 | |||||
